Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst, +94

The Lancet Respiratory Medicine

Autoimmune DiseaseSystemic SclerodermaImmunologySystemic SclerosisMultiple Sclerosis +1

Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study

Bogdan Batko, Marcin Stajszczyk, Jerzy Świerkot, +4

Archives of Medical Science

Factors associated with quality of life in systemic sclerosis: a cross-sectional study

Matylda Sierakowska, Halina Doroszkiewicz, Justyna Sierakowska, +13

Quality of Life Research

Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus

T. Mikołajczyk, Grzegorz Osmenda, Bogdan Batko, +6

Lupus

Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis

Bogdan Batko, Karol Urbański, Jerzy Świerkot, +7

Clinical Rheumatology

Rheumatoid DisorderRheumatologyFamily MedicineAutoimmune DiseaseHealth Policy +11

Mechanisms of increased vascular superoxide production in human varicose veins

Bartłomiej Guzik, Maciej Chwała, Paweł T. Matusik, +10

Polskie Archiwum Medycyny Wewnętrznej

Diagnostic delays in rheumatic diseases with associated arthritis

Filip Raciborski, Anna Kłak, Brygida Kwiatkowska, +10

Reumatologia/Rheumatology

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology

Eugeniusz J. Kucharz, Marcin Stajszczyk, Anna Kotulska-Kucharz, +8

Reumatologia/Rheumatology

Janus KinasesImmunologyPharmacotherapyInflammationActive Ra +16

Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment

Bogdan Batko, Karol Urbański, Natalia Ryszawa-Mrozek, +6

Scientific Reports

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

Rieke Alten, Bogdan Batko, Tomas Hala, +10

RMD Open